The Ahmedabad-based Zydus Cadila has entered into an alliance with Germany-based Pieris AG, a next generation therapeutic protein R&D company, for development and commercialisation of multiple novel Anticalin-based protein therapeutics. Pieris AG is an independent, clinical-stage biotechnology company advancing its proprietary Anticalin technology to create differentiated drugs that are safer and more effective than conventional approaches.
The collaboration combines Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing. Under the terms of the agreement, Zydus will take the lead in advancing Anticalin drug candidates through formal pre-clinical development and into clinical development, undertaking drug development in accordance with ICH guidelines. Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Pieris retains exclusive marketing rights in key developed markets.